U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897734) titled 'TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients' on Oct. 20.
Brief Summary: TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
NSCLC
RAS Mutation
MTAP Deletion
Lung Cancer
Pancreatic Cancer Metastatic
Thoracic Cancer
Intervention:
DRUG: vop...